In new research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.
This article was originally published on MedicalXpress.com

